pioglitazone has been researched along with Chronic Kidney Diseases in 14 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 7.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified." | 7.80 | The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014) |
| " Pioglitazone improves insulin sensitivity and it may have potential for treating CKD-related FGF23 overactivity." | 5.69 | Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial. ( Nata, N; Satirapoj, B; Supasyndh, O; Triwatana, W, 2023) |
| "Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone." | 3.81 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015) |
| "Although studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified." | 3.80 | The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. ( Hsiao, PJ; Lee, MY; Lin, KD; Shin, SJ; Yang, YH, 2014) |
| " Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects." | 2.87 | Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial. ( Satirapoj, B; Supasyndh, O; Watanakijthavonkul, K, 2018) |
| "Glucose-lowering treatment options for type 2 diabetes mellitus patients with chronic kidney disease are limited." | 2.80 | Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. ( Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H, 2015) |
| "Type 2 diabetes is a major risk factor for chronic kidney disease, which substantially increases the risk of cardiovascular disease mortality." | 2.79 | Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. ( Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D, 2014) |
| "Treatment with pioglitazone reduces the expression of ER stress markers and mitochondrial fusion proteins." | 1.51 | Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. ( Lee, JH; Lee, SH; Yoon, YM; Yun, CW, 2019) |
| "Pioglitazone is a type of peroxisome proliferator-activated receptor x03B3; agonist and is capable of alleviating renal ischemia-reperfusion injury." | 1.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model. ( Feng, J; Lu, C; Ma, J; Sun, L; Wang, D; Wang, L; Xu, T; Yao, L; Yuan, Q, 2016) |
| "With pioglitazone-treatment, diabetic animals remained euglycemic and treatment was able to reverse the clearance changes, although incompletely." | 1.42 | Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. ( Chadha, GS; Morris, ME, 2015) |
| "The metabolic syndrome is a risk factor for the development of chronic kidney disease." | 1.35 | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. ( Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Triwatana, W | 3 |
| Satirapoj, B | 4 |
| Supasyndh, O | 4 |
| Nata, N | 3 |
| Gor, D | 1 |
| Lee, TA | 1 |
| Schumock, GT | 1 |
| Walton, SM | 1 |
| Gerber, BS | 1 |
| Nutescu, EA | 1 |
| Touchette, DR | 1 |
| Yen, CL | 1 |
| Wu, CY | 1 |
| See, LC | 1 |
| Li, YJ | 1 |
| Tseng, MH | 1 |
| Peng, WS | 1 |
| Liu, JR | 1 |
| Chen, YC | 1 |
| Yen, TH | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Anderson, GF | 1 |
| Yang, HY | 1 |
| Zamami, Y | 1 |
| Imanishi, M | 1 |
| Takechi, K | 1 |
| Ishizawa, K | 1 |
| Watanakijthavonkul, K | 1 |
| Yoon, YM | 1 |
| Lee, JH | 1 |
| Yun, CW | 1 |
| Lee, SH | 1 |
| Lee, MY | 1 |
| Hsiao, PJ | 1 |
| Yang, YH | 1 |
| Lin, KD | 1 |
| Shin, SJ | 1 |
| Ruilope, L | 1 |
| Hanefeld, M | 1 |
| Lincoff, AM | 1 |
| Viberti, G | 1 |
| Meyer-Reigner, S | 1 |
| Mudie, N | 1 |
| Wieczorek Kirk, D | 1 |
| Malmberg, K | 1 |
| Herz, M | 1 |
| Chadha, GS | 1 |
| Morris, ME | 1 |
| McGill, JB | 1 |
| Yki-Järvinen, H | 1 |
| Crowe, S | 1 |
| Woerle, HJ | 1 |
| von Eynatten, M | 1 |
| Yamamoto, S | 1 |
| Zhong, J | 1 |
| Yancey, PG | 1 |
| Zuo, Y | 1 |
| Linton, MF | 1 |
| Fazio, S | 1 |
| Yang, H | 1 |
| Narita, I | 1 |
| Kon, V | 1 |
| Sun, L | 1 |
| Yuan, Q | 1 |
| Xu, T | 1 |
| Yao, L | 1 |
| Feng, J | 1 |
| Ma, J | 1 |
| Wang, L | 1 |
| Lu, C | 1 |
| Wang, D | 1 |
| Yasui, T | 1 |
| Okada, A | 1 |
| Hamamoto, S | 1 |
| Ando, R | 1 |
| Taguchi, K | 1 |
| Tozawa, K | 1 |
| Kohri, K | 1 |
| Namikoshi, T | 1 |
| Tomita, N | 1 |
| Satoh, M | 1 |
| Haruna, Y | 1 |
| Kobayashi, S | 1 |
| Komai, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®[NCT01043029] | Phase 2 | 302 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pioglitazone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological approach for drug repositioning against cardiorenal diseases.
Topics: Angiotensin Receptor Antagonists; Cardiovascular Diseases; Drug Repositioning; Humans; Insulin Resis | 2017 |
Pathophysiology-based treatment of urolithiasis.
Topics: Animals; Cardiovascular Diseases; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Disease Models, A | 2017 |
4 trials available for pioglitazone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibroblast Growth Factors; Humans; Insulin Resist | 2023 |
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, | 2018 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; | 2014 |
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-P | 2015 |
8 other studies available for pioglitazone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2020 |
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Cause of Death; Cohort Studies; Diabetes Mellit | 2020 |
Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients.
Topics: Adult; Antioxidants; Cell Proliferation; Endoplasmic Reticulum Stress; Female; Humans; Male; Mesench | 2019 |
The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
Topics: Adult; Aged; Asian People; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycem | 2014 |
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.
Topics: Administration, Intravenous; Animals; Biological Availability; Blood Glucose; Diabetes Mellitus, Exp | 2015 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle | 2015 |
Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model.
Topics: Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Down-Regulation; Hyp | 2016 |
Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dietary Protei | 2008 |